<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921946</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FMS-CT-116</org_study_id>
    <nct_id>NCT01921946</nct_id>
  </id_info>
  <brief_title>To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin</brief_title>
  <official_title>A Phase Ⅰ Study to Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase Ⅰ study to evaluate the pharmacokinetic interactions and safety between fimasartan&#xD;
      and rosuvastatin in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After subjects have signed informed consent voluntarily, they go through screening period for&#xD;
      within 21 days.&#xD;
&#xD;
      As period I, subjects of Part A take fimasartan for 7 days and subjects of Part B take&#xD;
      rosuvastatin for 7 days.&#xD;
&#xD;
      And then, after wash out for 7 days, as period II, subjects of both Part A and B take&#xD;
      fimasartan and rosuvastatin for 7 days.&#xD;
&#xD;
      At each period, subjects of Part A have blood sampling 2nd, 4th, 6th day before medication,&#xD;
      7th day before and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48hour after&#xD;
      medication(17 times in each period, 34 times in total).&#xD;
&#xD;
      At each period, subjects of Part B have blood sampling 2nd, 4th, 6th day before medication,&#xD;
      7th day before and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 8, 12, 24, 48 and 72hour after medication(17&#xD;
      times in each period, 34 times in total).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUC tau,ss),(Cmax,ss),(Cmin,ss), (Tmax,ss), (t1/2)</measure>
    <time_frame>0~72 hour after medication</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subject, aged 20- 55 years at screening.&#xD;
&#xD;
          2. Body weight of ≥ 50 kg and within ± 20% of ideal body weight (IBW)(kg) = {height (cm)&#xD;
             - 100} * 0.9&#xD;
&#xD;
          3. No abnormal symptom or sign, based on medical history and physical examination, with&#xD;
             no congenital or chronic disease that requires treatment&#xD;
&#xD;
          4. Subject that is considered appropriate for participating in the study by an&#xD;
             investigator, based on clinical laboratory test (serology, hematology, clinical&#xD;
             chemistry, urinalysis) and ECG, performed within 3 weeks prior to administration of&#xD;
             study drug&#xD;
&#xD;
          5. Subjects must be able to listen to and understand the detailed statement of informed&#xD;
             consent, and willing to decide to participate in the study, follow the study&#xD;
             directions and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant hypersensitivity to study drug, any other drug or&#xD;
             additives (yellow no.5).&#xD;
&#xD;
          2. History of any illness that may affect the absorption, distribution, metabolism or&#xD;
             excretion (hepatobiliary, renal, cardiovascular, endocrine (e.g., hypothyroidism),&#xD;
             respiratory, gastrointestinal, hemato-oncology, central nervous system, psychiatric&#xD;
             and musculoskeletal system)&#xD;
&#xD;
          3. Hypotension (systolic ≤ 100 mmHg or diastolic ≤ 65 mmHg) or hypertension (systolic ≥&#xD;
             140 mmHg or diastolic ≥ 90 mmHg), measured at screening&#xD;
&#xD;
          4. Active liver disease, or the levels of ALT(Aspartate Transaminase), AST (Alanin&#xD;
             Transaminase) or total bilirubin &gt; 1.5 x the upper limit of normal&#xD;
&#xD;
          5. Creatinine clearance &lt; 80 mL/min (calculated by Cockcroft-Gault formula using serum&#xD;
             creatinine)&#xD;
&#xD;
          6. Evidence of hereditary disease, including galactose intolerance, Lapp lactase&#xD;
             deficiency, or glucose-galactose malabsorption.&#xD;
&#xD;
          7. History of gastrointestinal disease (i.g., Crohn's disease, active peptic ulcer) or&#xD;
             resection operation that may affect the absorption of the study drug (excluding simple&#xD;
             appendectomy or herniorrhaphy)&#xD;
&#xD;
          8. History of major injury, surgical operation, or suspected symptom of acute illness&#xD;
             (severe infection, trauma, diarrhea or vomiting) within 4 weeks prior to the first&#xD;
             administration of study drug&#xD;
&#xD;
          9. History of excessive alcohol abuse (&gt;21 units/week, 1 unit=10g=12.5mL of pure&#xD;
             alcohol), or subjects who cannot abstain from drinking for at least 3 days prior to&#xD;
             the start of this study and throughout the study period, or excessive smoking (&gt;10&#xD;
             cigarettes/day)&#xD;
&#xD;
         10. Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any&#xD;
             over-the-counter medication within 1 week prior to the first administration of study&#xD;
             drug, and this will affect this study or the safety of the subjects in the opinion of&#xD;
             the investigator&#xD;
&#xD;
         11. Participation in any other study within 3 months prior to the first administration of&#xD;
             study drug (The finish time of previous study is the day of the last administration of&#xD;
             study drug)&#xD;
&#xD;
         12. Donation of whole blood within 2 months prior to the first administration of study&#xD;
             drug, or donation of any blood products within 1 month prior to the first&#xD;
             administration of study drug&#xD;
&#xD;
         13. Abnormal diet that may affect absorption, distribution, metabolism and excretion of&#xD;
             drugs (*e.g., Grapefruit juice ≥ 1L /day within 7 days prior to administration of&#xD;
             study drug)&#xD;
&#xD;
         14. Positive serologic tests (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)&#xD;
&#xD;
         15. Subject that is judged inappropriate for participating in the study by an&#xD;
             investigator, based on clinical laboratory test (serology, hematology, clinical&#xD;
             chemistry, urinalysis) or any other reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Ran Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>October 20, 2013</last_update_submitted>
  <last_update_submitted_qc>October 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

